{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T07:19:35Z","timestamp":1774855175699,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100012537","name":"Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan","doi-asserted-by":"crossref","award":["R100-7"],"award-info":[{"award-number":["R100-7"]}],"id":[{"id":"10.13039\/501100012537","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100012537","name":"Ditmanson Medical Foundation Chiayi Christian Hospital, Taiwan","doi-asserted-by":"crossref","award":["R101-9"],"award-info":[{"award-number":["R101-9"]}],"id":[{"id":"10.13039\/501100012537","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["NSC99-2321-B-194-001"],"award-info":[{"award-number":["NSC99-2321-B-194-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 103-2320-B-194-002"],"award-info":[{"award-number":["MOST 103-2320-B-194-002"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST 104-2314-B-194-001-MY3"],"award-info":[{"award-number":["MOST 104-2314-B-194-001-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.canlet.2015.09.018","type":"journal-article","created":{"date-parts":[[2015,10,22]],"date-time":"2015-10-22T05:32:10Z","timestamp":1445491930000},"page":"56-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3\u03b2 to suppress mTOR and \u03b2-catenin signaling pathways"],"prefix":"10.1016","volume":"370","author":[{"given":"Hsiao-Yen","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Huang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ru-Inn","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Min","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shih-Yuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuan-Hung","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Fen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Da","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.Y.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2015.09.018_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.urolonc.2010.06.012","article-title":"A cocktail regimen of intravesical mitomycin-C, doxorubicin, and cisplatin (MDP) for non-muscle-invasive bladder cancer","volume":"30","author":"Chen","year":"2012","journal-title":"Urol. Oncol"},{"key":"10.1016\/j.canlet.2015.09.018_bib0015","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0092-8674(00)00117-3","article-title":"TOR, a central controller of cell growth","volume":"103","author":"Schmelzle","year":"2000","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.09.018_bib0020","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1101\/gad.887201","article-title":"Regulation of translation initiation by FRAP\/mTOR","volume":"15","author":"Gingras","year":"2001","journal-title":"Genes Dev"},{"key":"10.1016\/j.canlet.2015.09.018_bib0025","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ccr.2007.07.006","article-title":"HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation","volume":"12","author":"Gordan","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2015.09.018_bib0030","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1038\/labinvest.2010.133","article-title":"Expanding therapeutic targets in bladder cancer: the PI3K\/Akt\/mTOR pathway","volume":"90","author":"Ching","year":"2010","journal-title":"Lab. Invest"},{"key":"10.1016\/j.canlet.2015.09.018_bib0035","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1158\/1535-7163.MCT-07-2408","article-title":"Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies","volume":"7","author":"Garcia","year":"2008","journal-title":"Mol. Cancer Ther"},{"key":"10.1016\/j.canlet.2015.09.018_bib0040","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.4161\/cbt.8.24.9987","article-title":"Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer","volume":"8","author":"Mansure","year":"2009","journal-title":"Cancer Biol. Ther"},{"key":"10.1016\/j.canlet.2015.09.018_bib0045","first-page":"142","article-title":"A comparison of the antipruritic efficacy of hydroxyzine and cyproheptadine in children with atopic dermatitis","volume":"44","author":"Klein","year":"1980","journal-title":"Ann. Allergy"},{"key":"10.1016\/j.canlet.2015.09.018_bib0050","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1002\/1097-0142(19900615)65:12<2657::AID-CNCR2820651210>3.0.CO;2-S","article-title":"A controlled trial of cyproheptadine in cancer patients with anorexia and\/or cachexia","volume":"65","author":"Kardinal","year":"1990","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2015.09.018_bib0055","first-page":"223","article-title":"A double blind controlled study of propranolol and cyproheptadine in migraine prophylaxis","volume":"48","author":"Rao","year":"2000","journal-title":"Neurol. India"},{"key":"10.1016\/j.canlet.2015.09.018_bib0060","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1182\/blood-2008-02-142687","article-title":"Cyproheptadine displays preclinical activity in myeloma and leukemia","volume":"112","author":"Mao","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2015.09.018_bib0065","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2012-007180","article-title":"Unexpected remission of hepatocellular carcinoma (HCC) with lung metastasis to the combination therapy of thalidomide and cyproheptadine: report of two cases and a preliminary HCC cell line study","volume":"2012","author":"Feng","year":"2012","journal-title":"BMJ Case Rep"},{"key":"10.1016\/j.canlet.2015.09.018_bib0070","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12885-015-1137-9","article-title":"Cyproheptadine, an antihistaminic drug, inhibits proliferation of hepatocellular carcinoma cells by blocking cell cycle progression through the activation of P38 MAP kinase","volume":"15","author":"Feng","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.canlet.2015.09.018_bib0075","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/ejh.12193","article-title":"Cyproheptadine-induced myeloma cell apoptosis is associated with inhibition of the PI3K\/AKT signaling","volume":"91","author":"Li","year":"2013","journal-title":"Eur. J. Haematol"},{"key":"10.1016\/j.canlet.2015.09.018_bib0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.devcel.2009.06.016","article-title":"Wnt\/beta-catenin signaling: components, mechanisms, and diseases","volume":"17","author":"MacDonald","year":"2009","journal-title":"Dev. Cell"},{"key":"10.1016\/j.canlet.2015.09.018_bib0085","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1158\/0008-5472.CAN-12-4198","article-title":"Constitutive beta-catenin activation induces male-specific tumorigenesis in the bladder urothelium","volume":"73","author":"Lin","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.canlet.2015.09.018_bib0090","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.cell.2006.06.055","article-title":"TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth","volume":"126","author":"Inoki","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.09.018_bib0095","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1073\/pnas.0405928102","article-title":"The Wnt\/beta-catenin signaling pathway targets PPARgamma activity in colon cancer cells","volume":"102","author":"Jansson","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.09.018_bib0100","doi-asserted-by":"crossref","first-page":"5827","DOI":"10.1128\/MCB.00441-06","article-title":"Functional interaction between peroxisome proliferator-activated receptor gamma and beta-catenin","volume":"26","author":"Liu","year":"2006","journal-title":"Mol. Cell. Biol"},{"key":"10.1016\/j.canlet.2015.09.018_bib0105","doi-asserted-by":"crossref","first-page":"5343","DOI":"10.1128\/MCB.20.14.5343-5349.2000","article-title":"Peroxisome proliferator-activated receptor gamma target gene encoding a novel angiopoietin-related protein associated with adipose differentiation","volume":"20","author":"Yoon","year":"2000","journal-title":"Mol. Cell. Biol"},{"key":"10.1016\/j.canlet.2015.09.018_bib0110","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1186\/1476-4598-13-196","article-title":"Clinical relevance and therapeutic potential of angiopoietin-like protein 4 in hepatocellular carcinoma","volume":"13","author":"Ng","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2015.09.018_bib0115","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1126\/science.274.5293.1672","article-title":"Cancer cell cycles","volume":"274","author":"Sherr","year":"1996","journal-title":"Science"},{"key":"10.1016\/j.canlet.2015.09.018_bib0120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2184.2003.00267.x","article-title":"Cell cycle and apoptosis","volume":"36","author":"Vermeulen","year":"2003","journal-title":"Cell Prolif"},{"key":"10.1016\/j.canlet.2015.09.018_bib0125","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/carcin\/bgp258","article-title":"Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk","volume":"30","author":"Chen","year":"2009","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2015.09.018_bib0130","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s00345-008-0285-9","article-title":"Serotonin used as prognostic marker of urological tumors","volume":"26","author":"Jungwirth","year":"2008","journal-title":"World J. Urol"},{"key":"10.1016\/j.canlet.2015.09.018_bib0135","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1464-410X.2006.06056.x","article-title":"The effect of serotonin and serotonin antagonists on bladder cancer cell proliferation","volume":"97","author":"Siddiqui","year":"2006","journal-title":"BJU Int"},{"key":"10.1016\/j.canlet.2015.09.018_bib0140","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0736-4679(98)00057-2","article-title":"Treatment of the serotonin syndrome with cyproheptadine","volume":"16","author":"Graudins","year":"1998","journal-title":"J. Emerg. Med"},{"key":"10.1016\/j.canlet.2015.09.018_bib0145","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nm.2160","article-title":"Recovery of motoneuron and locomotor function after spinal cord injury depends on constitutive activity in 5-HT2C receptors","volume":"16","author":"Murray","year":"2010","journal-title":"Nat. Med"},{"key":"10.1016\/j.canlet.2015.09.018_bib0150","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1248\/cpb.45.842","article-title":"Synthesis, affinity at 5-HT2A, 5-HT2B and 5-HT2C serotonin receptors and structure-activity relationships of a series of cyproheptadine analogues","volume":"45","author":"Honrubia","year":"1997","journal-title":"Chem. Pharm. Bull"},{"key":"10.1016\/j.canlet.2015.09.018_bib0155","doi-asserted-by":"crossref","first-page":"915","DOI":"10.18632\/oncotarget.2821","article-title":"DNA methylome analysis identifies epigenetic silencing of FHIT as a determining factor for radiosensitivity in oral cancer: an outcome-predicting and treatment-implicating study","volume":"6","author":"Lin","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.canlet.2015.09.018_bib0160","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1101\/gad.13.14.1768","article-title":"Wnt-induced dephosphorylation of axin releases beta-catenin from the axin complex","volume":"13","author":"Willert","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.canlet.2015.09.018_bib0165","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1073\/pnas.96.10.5522","article-title":"The cyclin D1 gene is a target of the beta-catenin\/LEF-1 pathway","volume":"96","author":"Shtutman","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.09.018_bib0170","doi-asserted-by":"crossref","first-page":"7137","DOI":"10.3748\/wjg.v20.i23.7137","article-title":"Emerging role of the beta-catenin-PPARgamma axis in the pathogenesis of colorectal cancer","volume":"20","author":"Sabatino","year":"2014","journal-title":"World J. Gastroenterol"},{"key":"10.1016\/j.canlet.2015.09.018_bib0175","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2141.2009.07797.x","article-title":"The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor","volume":"146","author":"Paoluzzi","year":"2009","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.canlet.2015.09.018_bib0180","doi-asserted-by":"crossref","first-page":"31263","DOI":"10.1074\/jbc.M202528200","article-title":"The proto-oncogene c-myc acts through the cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) to facilitate the activation of Cdk4\/6 and early G(1) phase progression","volume":"277","author":"Obaya","year":"2002","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.09.018_bib0185","doi-asserted-by":"crossref","first-page":"37330","DOI":"10.1074\/jbc.M605569200","article-title":"Molecular mechanism of adaphostin-mediated G1 arrest in prostate cancer (PC-3) cells: signaling events mediated by hepatocyte growth factor receptor, c-Met, and p38 MAPK pathways","volume":"281","author":"Mukhopadhyay","year":"2006","journal-title":"J. Biol. Chem"},{"key":"10.1016\/j.canlet.2015.09.018_bib0190","doi-asserted-by":"crossref","first-page":"7900","DOI":"10.1073\/pnas.89.17.7900","article-title":"Phosphorylation of the retinoblastoma protein by cdk2","volume":"89","author":"Akiyama","year":"1992","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.09.018_bib0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1091\/mbc.8.2.287","article-title":"Cyclin D1\/Cdk4 regulates retinoblastoma protein-mediated cell cycle arrest by site-specific phosphorylation","volume":"8","author":"Connell-Crowley","year":"1997","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.canlet.2015.09.018_bib0200","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/0092-8674(93)90499-G","article-title":"The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases","volume":"75","author":"Harper","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2015.09.018_bib0205","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2015.09.018_bib0210","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/18884","article-title":"Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells","volume":"398","author":"Tetsu","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.canlet.2015.09.018_bib0215","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1158\/1078-0432.CCR-10-0275","article-title":"Glycogen synthase kinase-3beta: a prognostic marker and a potential therapeutic target in human bladder cancer","volume":"16","author":"Naito","year":"2010","journal-title":"Clin. Cancer Res"},{"key":"10.1016\/j.canlet.2015.09.018_bib0220","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1158\/1541-7786.MCR-11-0519","article-title":"Emerging roles of angiopoietin-like 4 in human cancer","volume":"10","author":"Tan","year":"2012","journal-title":"Mol. Cancer Res"},{"key":"10.1016\/j.canlet.2015.09.018_bib0225","doi-asserted-by":"crossref","first-page":"18721","DOI":"10.1073\/pnas.0609025103","article-title":"Angiopoietin-like 4 prevents metastasis through inhibition of vascular permeability and tumor cell motility and invasiveness","volume":"103","author":"Galaup","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.canlet.2015.09.018_bib0230","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.drup.2008.03.001","article-title":"Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment","volume":"11","author":"Jiang","year":"2008","journal-title":"Drug Resist. Updat"},{"key":"10.1016\/j.canlet.2015.09.018_bib0235","doi-asserted-by":"crossref","first-page":"5497","DOI":"10.1038\/onc.2008.245","article-title":"PI3K pathway alterations in cancer: variations on a theme","volume":"27","author":"Yuan","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.canlet.2015.09.018_bib0240","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.cellsig.2009.01.004","article-title":"Akt-dependent and -independent mechanisms of mTOR regulation in cancer","volume":"21","author":"Memmott","year":"2009","journal-title":"Cell. Signal"},{"key":"10.1016\/j.canlet.2015.09.018_bib0245","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1101\/gad.230302","article-title":"Axin-mediated CKI phosphorylation of beta-catenin at Ser 45: a molecular switch for the Wnt pathway","volume":"16","author":"Amit","year":"2002","journal-title":"Genes Dev"},{"key":"10.1016\/j.canlet.2015.09.018_bib0250","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0092-8674(02)00685-2","article-title":"Control of beta-catenin phosphorylation\/degradation by a dual-kinase mechanism","volume":"108","author":"Liu","year":"2002","journal-title":"Cell"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515006096?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383515006096?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:36:38Z","timestamp":1759592198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383515006096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0304383515006096"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2015.09.018","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyproheptadine exhibits antitumor activity in urothelial carcinoma cells by targeting GSK3\u03b2 to suppress mTOR and \u03b2-catenin signaling pathways","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2015.09.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}